Israel

MigVax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

OurCrowd Launches $100 Million Pandemic Innovation Fund

Lead Product(s): MigVax-101

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: OurCrowd

Deal Size: $100.0 Million Upfront Cash: Undisclosed

Deal Type: Funding June 02, 2020

Details:

First investments to include MigVax - Israeli contender to produce oral coronavirus vaccine, and Sight Diagnostics - rapid, accurate and safe blood test technology in use at hospitals with COVID-19 patients.

Kamada

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product

Lead Product(s): Anti-SARS-CoV-2 polyclonal immunoglobulin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Kedrion

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2020

Details:

Kedrion will supply plasma from convalescent COVID-19. Kamada will be responsible for development, manufacturing and distribution of the product in territories not under kedrion’s responsibility.

MigVax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: OurCrowd

Deal Size: $12.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 22, 2020

Details:

Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

Lead Product(s): Opaganib,Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.

SuperTrans Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Korean firm invests $2M in SuperTrans Medical

Lead Product(s): Antibiotics

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Mediforum Pharm

Deal Size: $2.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration April 10, 2020

Details:

SuperTrans is completing a candidate evaluation of COVID-19 therapy based on its transmission technology.

Pluristem Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment

Lead Product(s): PLX cells

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2020

Details:

Pre-clinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal in COVID-19 infection.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

MigVax

OurCrowd Launches $100 Million Pandemic Innovation Fund

Kamada

Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product

MigVax

OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

RedHill Biopharma

Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

SuperTrans Medical

Korean firm invests $2M in SuperTrans Medical

Pluristem Therapeutics

Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment